| |
| . |
 24  1/2  |
|
|
|
Subject |
Hyundai Pharm entered technology transfer agreement with Catholic University of Korea Industry & Academy Collaboration. |
Content |
Hyundai Pharm entered technology transfer agreement with Catholic University of Korea Industry & Academy Collaboration
- Challenging Obesity Market with ‘Obesity Prevention & Treatment Composition’ Patent Study/Collaboration
On 14th at at the Catholic University of Korea Professor Conference Room, Hyundai Pharm (President Yeong Hak Kim) entered “Obesity Prevention and Treatable Composition” patent technology transfer agreement with Catholic University of Korea Industry & Academy Collaboration.
In this ceremony, Hyundai Pharm’s representatives in R&D team and Catholic University of Korea R&D team decided to discuss future collaboration plans and goals for obesity treatment development.
This technology supported with Catholic University of Korea Medical School Jun Ki Min and Mi Ra Jo Professors and their teams funded by Health & Medical Technology R&D business, is found to have a drastically weight loss effect compared with placebo. While it reduces ratio of white fat which stores extra fat and increases ratio of brown fat which provides energy by burning fat from the animal studies and now it has its own patent.
Yeong Hak Kim, President of Hyundai Pharm, said “It is expected that as the global obesity population increases, obesity treatment market will have continuous growth potential. Through this technology transfer verifying candidate substance and conduct dose form optimal studies by applying R&D know-hows; it is planned to go for anti-obesity treatment market globally at the end of 2019 after going through non-clinical & clinical studies.
|
Date |
2015-04-17 |
|
 |
 |
 |
|
